Table 1.
Demographics and lifestyle characteristics of cases and controls of the Prostate Cancer Prevention Trial participants in the treatment arm (n = 1273).
Table 2.
Mean finasteride levels (ng/mL) stratified by categories of demographic measures among treatment-compliant men in the Prostate Cancer Prevention Trial finasteride arm.
Table 3.
Associations of finasteride concentrations with prostate cancer risk in PCPT, overall and stratified by cancer grade.
Table 4.
Association between finasteride concentrations and genes in metabolism and target pathways among white men. #
Fig 1.
Linkage disequilibrium (LD) pattern and haplotype architecture for (A) CYP3A4 & CYP3A5; (B) SRD5A2; and (C) SRD5A2L/SRD5A3 genes.
The haplotype block structure, as exhibited by Haploview is shown. LD was measured using data from all white subjects in the present study. The haplotype blocks were determined using the criteria described by Gabriel et al. The physical position of each SNP is presented in the upper diagram. Each diamond contains the level of LD measured by Hedrick's multiallelic D′ between pairs of single nucleotide polymorphisms. Shading shows the magnitude and significance of pairwise LD, with darker shades representing stronger LD; the diamond without a number corresponds to D′ = 1. Haplotypes for the variations and their population frequency (light gray color) are shown below each haplotype block of the corresponding genes. The SNP numbers across the top of the haplotypes correspond to those in the Haploview plot. D′ indicates the level of recombination between two blocks and is shown in the crossing area. The connection from one block to the next block is displayed through frequency corresponding to the thickness of the line.